Target intelligence / Profile preview

Other mRNAs with partial seed complementarity

Molecular classification
Messenger RNA
01

Overview

Other mRNAs with partial seed complementarity refers to a broad class of unintended genetic targets that are silenced by small interfering RNAs (siRNAs) or microRNAs (miRNAs) through sequence-specific interactions. This phenomenon, often termed "seed-mediated off-target effects," occurs when the seed region of the oligonucleotide guide strand (nucleotides 2-8) binds to complementary sequences in the 3' untranslated regions (UTRs) of non-target mRNAs (Jackson et al., 2003, Nature Biotechnology). Once bound, these off-target mRNAs are processed by the RNA-induced silencing complex (RISC), resulting in mRNA degradation or the inhibition of protein translation. In the field of oligonucleotide therapeutics, these interactions are a primary source of sequence-specific toxicity and can lead to adverse clinical outcomes such as hepatotoxicity (Janas et al., 2018, Nature Communications). To minimize these risks, drug developers employ chemical modifications, such as 2'-O-methyl substitutions at the second nucleotide of the guide strand, to destabilize off-target binding while maintaining on-target potency. Understanding and predicting these interactions through bioinformatic screening is a critical component of the safety assessment for any RNA-based therapeutic (Setten et al., 2019, Nature Reviews Drug Discovery).

Other names
Off-target mRNAsSeed-mediated off-targetsmiRNA-like off-target effectsTranscriptome-wide off-targets
02

Mechanism of action

The guide strand of an siRNA or miRNA incorporates into the RNA-induced silencing complex (RISC) and utilizes its "seed region" (nucleotides 2-8) to bind via partial complementarity to the 3' untranslated regions (UTRs) of unintended mRNAs, leading to their degradation or translational repression (Birmingham et al., 2006, Nature Methods; Jackson et al., 2003, Nature Biotechnology).

03

Biological functions

Post-transcriptional gene silencingRNA interferenceTranslation inhibition
04

Disease associations

Drug-induced toxicityAdverse drug reactions
05

Safety considerations

Unintended gene silencingHepatotoxicityOff-target toxicitySaturation of the RNAi machinery (Setten et al., 2019, Nature Reviews Drug Discovery)
06

Interacting drugs

Patisiran

4 more in the full profile.

07

Biomarkers

Transcriptome profiling (RNA-seq)Alanine aminotransferase (ALT)Aspartate aminotransferase (AST)

Beyond the preview

Go deeper on Other mRNAs with partial seed complementarity.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Other mRNAs with partial seed complementarity.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call